Brooklyn Asset Turnover Trend from 2010 to 2022

BTX
 Stock
  

USD 0.55  0.04  6.78%   

Brooklyn Immunotherapeuti Asset Turnover yearly trend continues to be fairly stable with very little volatility. Asset Turnover is likely to outpace its year average in 2022. During the period from 2010 to 2022, Brooklyn Immunotherapeuti Asset Turnover regression line of anual values had r-squared of 0.68 and arithmetic mean of  1.49. Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.5 M) in 2022.
  
Refresh
Check Brooklyn Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brooklyn main balance sheet or income statement drivers, such as Direct Expenses of 541.5 K, Cost of Revenue of 9.2 M or Gross Profit of 12.2 M, as well as many exotic indicators such as Long Term Debt to Equity of 3.0E-4, PPandE Turnover of 1.03 or Receivables Turnover of 11.02. Brooklyn financial statements analysis is a perfect complement when working with Brooklyn Immunotherapeuti Valuation or Volatility modules. It can also supplement various Brooklyn Immunotherapeuti Technical models. Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors.

Brooklyn Asset Turnover Breakdown

Showing smoothed Asset Turnover of Brooklyn Immunotherapeutics with missing and latest data points interpolated. Asset turnover is a measure of a firms operating efficiency; calculated by dividing Revenues by Average Assets. Often a component of DuPont ROE analysis.Brooklyn Immunotherapeuti's Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brooklyn Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
Asset Turnover10 Years Trend
Decreasing
Slightly volatile
 Asset Turnover 
Share
      Timeline 

Brooklyn Asset Turnover Regression Statistics

Arithmetic Mean 1.49
Geometric Mean 1.47
Coefficient Of Variation 19.76
Mean Deviation 0.25
Median 1.38
Standard Deviation 0.29
Sample Variance 0.09
Range 0.73
R-Value(0.83)
Mean Square Error 0.029921
R-Squared 0.68
Significance 0.00048863
Slope(0.06)
Total Sum of Squares 1.04

Brooklyn Asset Turnover History

2013 1.89
2014 1.26
2015 1.38
2016 1.43
2017 1.21
2018 1.49
2019 1.3
2021 1.17

About Brooklyn Immunotherapeuti Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brooklyn Immunotherapeuti income statement, its balance sheet, and the statement of cash flows. Brooklyn Immunotherapeuti investors use historical funamental indicators, such as Brooklyn Immunotherapeuti's Asset Turnover, to determine how well the company is positioned to perform in the future. Although Brooklyn Immunotherapeuti investors may use each financial statement separately, they are all related. The changes in Brooklyn Immunotherapeuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brooklyn Immunotherapeuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brooklyn Immunotherapeuti Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brooklyn Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Asset Turnover 1.17  1.26 
Average Assets39.3 M42.4 M
Tangible Asset Value30.4 M24.3 M
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now

   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.